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ABSTRACT.
Purpose: To assess macular thinning in individuals with prediabetes or type 2
diabetes without diabetic retinopathy (DM2 w/o DR) compared with individuals
with normal glucose metabolism (NGM).
Methods: Using spectral domain optical coherence tomography (SD-OCT), we
measured macular thickness in six subfields as defined by the Early Treatment
Diabetic Retinopathy Study (ETDRS) in 1838 participants from The Maastricht
Study, a population-based cohort study (mean age 59  8 years, 49% men,
1087 NGM, 279 prediabetes, 472 DM2 w/o DR). Multivariable linear
regression was used to assess the association between macular thickness and
glucose metabolism status.
Results: After adjustment for age, sex and spherical equivalent, individuals with
prediabetes showed a significant decrease in pericentral superior macular
thickness [b = 2.14 lm (95% confidence interval (CI): 4.24 to 0.03),
p < 0.05] compared with individuals with NGM. In individuals with DM2 w/o
DR, the fovea [b = 4.05 lm (95% CI: 6.30 to 1.79), p < 0.001] and the
four pericentral quadrants (range: b = 4.64 to 5.29 lm, p < 0.001) were
significantly thinner compared with individuals with NGM. There was a
significant linear trend of macular thinning with severity of glucose metabolism
status in five subfields (p < 0.001).
Conclusion: Macular thickness is reduced in prediabetes and a greater reduction
occurs in DM2, even before DR is clinically present. About half of the thinning
observed in DM2 w/o DR was already found in prediabetes. Generalized
thinning of the macula could be related to thinning of the temporal side of the
optic nerve head through the connecting papillo-macular bundle.
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Introduction
Diabetic retinopathy (DR) is a severe
complication of diabetes and often
goes unnoticed until visual loss occurs.
The historical definition of early DR
is based on the presence of
microaneurysms, which can be detected
by ophthalmoscopic examination.
However, in 1980, Simonsen et al.
showed the predictive value of the
oscillatory potential in the develop-
ment of proliferative DR (Frost-Larsen
et al. 1980; Simonsen 1980) and in
1986, Bresnick et al. proposed DR to
primarily be a neurosensory disorder
(Bresnick 1986). Also visual acuity,
dark adaptation and colour vision are
impaired in individuals with diabetes
(Henson & North 1979; Sokol et al.
1985; Bresnick 1986; Hardy et al. 1992;
Han et al. 2004a,b; Realini et al. 2004;
Klemp et al. 2005; Bearse et al. 2006;
Ng et al. 2008; Vujosevic et al. 2008;
Harrison et al. 2011). These early func-
tional deficits could be related to
structural changes in the retina as
revealed by optical coherence tomog-
raphy (OCT) in individuals with dia-
betes. Recent studies suggest that
thinning of the neuronal layers of the
retina is an early event in the patho-
genesis of DR, as these retinal neu-
rodegenerative changes occur even
before microvascular lesions can be
detected with funduscopy (Barber et al.
1998; Carrasco et al. 2007, 2008; Gar-
cia-Ramirez et al. 2009; De Clerck
et al. 2015). Therefore, DR has
recently been redefined as ‘structural
and functional changes in the retina
due to diabetes’ (Gardner et al. 2011).
Recently, we observed a linear trend
of retinal nerve fibre layer (RNFL)
thinning around the optic nerve head
with worsening of glucose regulation,
predominantly at the temporal side of
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the optic nerve head (De Clerck et al.
2017). One can hypothesize that also in
the macula, retinal neurodegeneration
is already present in prediabetes, a
stage of glucose dysregulation that
occurs before type 2 diabetes. How-
ever, population-based studies of mac-
ular thickness and glucose metabolism
are not available. Establishing changes
in macular thickness in individuals with
prediabetes and in individuals with
DM2 w/o DR could open new per-
spectives for understanding the early
pathogenesis of DR.
The aim of this study was to evalu-
ate to what extent macular thinning
occurs in individuals with DM2 w/o
DR and also in individuals with predi-
abetes, as compared to individuals with
NGM in a large population-based
cohort study.
Materials and Methods
Study population and design
In this study, we used data from The
Maastricht Study, an observational
prospective population-based cohort
study. The rationale and methodology
have been described previously
(Schram et al. 2014). In brief, the study
focuses on the aetiology, pathophysi-
ology, complications and comorbidities
of DM2 and is characterized by an
extensive phenotyping approach. Eligi-
ble for participation were all individu-
als aged between 40 and 75 years and
living in the southern part of The
Netherlands. Participants were
recruited through mass media cam-
paigns and from the municipal reg-
istries and the regional Diabetes
Patient Registry via mailings. Recruit-
ment was stratified according to known
DM2 status for reasons of efficiency.
This report includes cross-sectional
data from the first 3451 participants,
who completed the baseline survey
between November 2010 and Septem-
ber 2013. The examinations of each
participant were performed within a
time window of 3 months. The study
has been approved by the institutional
medical ethical committee
(NL31329.068.10) and the Minister of
Health, Welfare and Sports of The
Netherlands, on the basis of the Health
Council’s opinion (Permit 131088-
105234-PG) and is compliant with the
tenets of the Declaration of Helsinki.
All participants gave written informed
consent.
Glucose metabolism status
To determine glucose metabolism sta-
tus, all participants, except those who
used insulin, underwent a standard-
ized 2-hr 75 g oral glucose tolerance
test (OGTT) after an overnight fast.
For safety reasons, participants with a
fasting glucose level above 11.0 mmol/
l, as determined by a finger prick, did
not undergo the OGTT. For these
individuals (n = 13), fasting glucose
level and information about diabetes
medication were used to determine
glucose metabolism status. Glucose
metabolism status was defined
according to the WHO (2006) criteria
into NGM, impaired fasting glucose
(IFG), impaired glucose tolerance
(IGT), prediabetes (i.e. IFG and/or
IGT) and DM2 (2006). For this study,
individuals with DM1, individuals
with latent autoimmune diabetes of
adults, steroid-induced diabetes and
individuals who underwent a pancreas
transplantation were excluded.
Ophthalmologic measurements
Automated refraction was performed
in both eyes using an automated
refractor (Tonoref II; Nidek, Gam-
agori, Japan). Once the pupils were
dilated with tropicamide 0.5% and
phenylephrine 2.5%, fundus photogra-
phy of both eyes was performed. All
fundus photographs were made with an
auto fundus camera (Model AFC-230;
Nidek) in 45 degrees of at least three
fields: one field centred on the optic
disc, one field centred on the macula
and one temporal field positioned one
disc-diameter from the centre of the
macula. Diabetic retinopathy (DR) was
graded according to the DR Disease
Severity Scale and International Clini-
cal DR Disease Severity Scale (Amer-
ican Academy of Ophthalmology
Retina/Vitreous Panel 2014). Next, all
participants were examined with the
Spectralis OCT (Heidelberg Engineer-
ing, Heidelberg, Germany, Heidelberg
Eye Explorer software version 5.7.5.0)
with the eye tracking function enabled.
A macular volume scan (17 ART, 73
sections, 60 lm) was performed in both
eyes by experienced examiners masked
to the conditions of the participants.
Regional numeric data of the macular
thickness were derived from the Mac-
ular Thickness Map (Massin et al.
2002). With use of the Macular Thick-
ness Map, macular thickness was mea-
sured at the centre, the fovea and in the
four pericentral subfields as defined by
ETDRS (Fig. 1). The cross-sections of
the macular volume scans were
reviewed and scored for the presence
of cysts by two experienced graders in a
masked fashion based on a prespecified
protocol. Individuals with an incom-
plete volume scan (<73 sections), poor
quality imaging (signal-to-noise ratio
<20 dB), unsatisfactory automatic real-
time tracking (<15) and retinal disor-
ders (i.e. epiretinal membrane, cysts,
DR or previous laser treatment) were
excluded.
Reproducibility was assessed by two
observers in both eyes of nine individ-
uals (seven men, 56.0  5.5 years; four
individuals with DM2) who were
examined on two occasions spaced
1 week apart. The intra-observer and
interobserver intraclass correlation
coefficients were ≥0.99 for all macular
thicknesses in both eyes.
Statistical analysis
Statistical analysis was performed in
SPSS Statistics 23 for Windows (SPSS,
IBM, Armonk, NY, USA). Differences
between group characteristics were
tested using one-way analysis of vari-
ance (ANOVA) for continuous vari-
ables and chi-squared tests for
categorical variables. Multivariable lin-
ear regression was used to analyse the
association between glucose metabo-
lism status (prediabetes and DM2 w/o
DR; determinant) and macular thick-
ness (outcome). We combined the cat-
egories IFG and IGT into prediabetes,
because analyses did not show differ-
ences between IFG and IGT (data not
shown). First, a crude analysis was
performed. Next, associations were
adjusted for age, sex and spherical
equivalent by adding these variables
as covariates to the model. Interactions
between age, sex, spherical equivalent
and glucose metabolism status were
tested. The results were expressed as
regression coefficients (b), representing
the mean difference in macular thick-
ness as compared with individuals with
NGM, with their 95% CIs. A p value
<0.05 was considered statistically
significant.
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Results
General characteristics
Figure 2 shows the flow diagram of the
study. From December 2011 to
September 2013, 2363 participants
from The Maastricht Study underwent
OCT measurement. Forty-one partici-
pants with DM1 or other types of
diabetes were excluded. Participants
with an incomplete volume scan
(n = 161) or an unsatisfactory quality
of measurement (n = 5) were also
excluded. In addition, individuals with
retinal disorders (n = 160) were
excluded –that is epiretinal membrane
(n = 92), cysts (n = 42), DR (n = 40)
and/or previous laser treatment
(n = 18). We additionally excluded
individuals where data on the spherical
equivalent were missing (n = 158).
Thus, 1838 participants were available
for analysis with adjustment for age,
sex and spherical equivalent. Partici-
pants who were excluded due to miss-
ing values were more likely to be older
(60  8 versus 59  8 years, p <
0.01), to be male (54% versus 49%
men, p < 0.01) and to have a lower
spherical equivalent (0.60  2.92 ver-
sus 0.27  2.49 D, p < 0.01).
Of the 1838 participants, 1087 par-
ticipants had NGM (59.1%), 279 par-
ticipants had prediabetes (15.2%), and
472 participants had DM2 w/o DR
(25.7%). Differences in characteristics
among these three groups are shown in
Table 1.
Macular thickness
Table 2 shows crude associations
between glucose metabolism status
and centre thickness, foveal thickness
and the four pericentral macular thick-
nesses. In individuals with NGM, mean
macular thicknesses were as follows:
centre thickness 233.4 lm (95% CI:
232.2–234.6), foveal thickness
284.5 lm (95% CI: 283.2–285.7), peri-
central nasal macular thickness
OD
S
N
I
T
F
C
Fig. 1. Illustration of the region in the ETDRS grid from which data were gathered for the volume
scan in a right eye. The blue area represents the area from which data were gathered. The two
regions in the centre constitute the central macula. The four regions around the fovea constitute the
pericentral macula. Point C = centre thickness, Region F = foveal thickness, Region I = pericen-
tral inferior macular thickness, Region N = pericentral nasal macular thickness, Region,
S = pericentral superior macular thickness, Region T = pericentral temporal macular thickness.
Study population fromThe Maastricht Study with OCT measurements from December 2011 to September 2013 (n = 2363)
Exclusion criteria:
- Type 1 diabetes/other type of diabetes (n = 37/4)
- Incomplete scan (n = 161)
- Unsatisfactory quality (n = 5)
- Retinal disorders (n = 160)
- Missing data on spherical equivalent (n = 158)
Study population with valid macular measurements (n = 1838) with 1087 NGM, 279 prediabetes and 472 DM2 w/o DR
Fig. 2. Flow diagram of the study. DM2 w/o DR = type 2 diabetes mellitus without diabetic retinopathy, NGM = normal glucose metabolism,
OCT = optical coherence tomography.
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350.4 lm (95% CI: 349.4–351.3), peri-
central superior macular thickness
347.3 lm (95% CI: 346.4–348.3), peri-
central temporal macular thickness
336.1 lm (95% CI: 335.2–337.0) and
pericentral inferior macular thickness
345.0 lm (95% CI: 344.0–345.9). All
pericentral macular thickness values
were significantly lower in individuals
with prediabetes and in individuals with
DM2 w/o DR compared with individ-
uals with NGM (p < 0.05), except for
the pericentral temporal macular thick-
ness in individuals with prediabetes
(p = 0.06). The mean macular thick-
nesses of the right eye were very similar
to the mean macular thicknesses of the
left eye (data not shown).
Figure 3 shows crude pericentral
macular thicknesses according to glu-
cose metabolism status. Thinning of
the macula was more pronounced with
worsening of glucose metabolism sta-
tus, with a highly significant p-value for
linear trend for all quadrants
(p < 0.001).
Age was significantly associated with
macular thinning of all pericentral
macular thicknesses (range: b = 0.33
to 0.41 per 1 year of age, p < 0.001).
In women, all macular thicknesses
were thinner compared with men,
especially at the fovea (range:
b = 1.03 to 12.22 lm, p ≤ 0.01).
Macular thinning in women was not
significant in the superior quadrant
(b = 1.03, p = 0.18). Per dioptre
decrease in spherical equivalent, the
pericentral macular thickness was 0.16–
0.19 lm thinner. However, the associ-
ation between spherical equivalent and
macular thickness was not significant
(p > 0.05). In individuals with DM2 w/
o DR, the four pericentral quadrants
were significantly associated with dura-
tion of diabetes (range: b = 0.36 to
0.42 lm per 1 year of duration,
p < 0.05).
Table 2 also shows associations
adjusted for age, sex and spherical
equivalent between glucose metabolism
status and centre thickness, foveal
thickness and the four pericentral mac-
ular thicknesses. After adjustment for
age, sex and spherical equivalent, indi-
viduals with prediabetes showed a sta-
tistically significant decrease in
pericentral superior macular thickness
[b = 2.14 lm (95% CI: 4.24 to
0.03), p < 0.05] compared with indi-
viduals with NGM. In individuals with
DM2 w/o DR, the fovea and the four
pericentral quadrants were significantly
Table 1. Baseline characteristics of the study population, stratified by glucose metabolism status.
NGM (N = 1087)
Prediabetes
(N = 279)
DM2 w/o DR
(N = 472)
p-value
(Prediabetes
versus NGM)
p-value (DM2 w/o
DR versus NGM)
Age (years), mean (SD) 57.7 (8.0) 60.8 (7.4) 62.3 (7.8) <0.001 <0.001
Male sex, n (%) 441 (40.6) 149 (53.4) 307 (65.0) <0.001 <0.001
Spherical equivalent (D), mean (SD) 0.42 (2.48) 0.18 (2.48) 0.04 (2.49) 0.16 <0.01
Diabetes duration (years), median (IQR)* – – 4.0 (0.0–8.0) – –
D = dioptre, DM2 w/o DR, type 2 diabetes without diabetic retinopathy, IQR = interquartile range, NGM = normal glucose metabolism,
SD = standard deviation.
* Availiable for 363 participants with DM2.
Table 2. Mean difference of macular thickness between individuals with prediabetes and type 2 diabetes without diabetic retinopathy versus normal
glucose metabolism adjusted for age, sex and spherical equivalent.
Crude analysis Adjustment for age, sex, and spherical equivalent
Prediabetes DM2 w/o DR Trend Prediabetes DM2 w/o DR Trend
b (95% CI) b (95% CI) p b (95% CI) b (95% CI) p
Center thickness
(lm)
0.67 (3.44 to 2.11) 0.48 (2.75 to 1.80) 0.64 1.20 (3.96 to 1.55) 1.65 (4.00 to 0.69) 0.15
Foveal thickness
(lm)
0.93 (3.67 to 1.82) 1.06 (3.32 to 1.20) 0.33 2.48 (5.13 to 0.17) 4.05 (6.30 to 1.79)* <0.001
Pericentral nasal
macular
thickness (lm)
2.47 (4.60 to 0.34)* 5.16 (6.90 to 3.41)* <0.001 1.92 (4.02 to 0.18) 4.64 (6.43 to 2.85)* <0.001
Pericentral
superior macular
thickness (lm)
2.90 (5.02 to 0.78)* 6.20 (7.94 to 4.45)* <0.001 2.14 (4.24 to 0.03)* 5.29 (7.08 to 3.50)* <0.001
Pericentral
temporal macular
thickness (lm)
1.90 (3.91 to 0.11) 4.78 (6.43 to 3.12)* <0.001 1.64 (3.62 to 0.34) 4.76 (6.44 to 3.07)* <0.001
Pericentral
inferior macular
thickness (lm)
2.31 (4.43 to 0.18)* 5.46 (7.21 to 3.72)* <0.001 1.59 (3.68 to 0.51) 4.67 (6.45 to 2.89)* <0.001
b = regression coefficient, 95% CI = 95% confidence interval, DM2 w/o DR = type 2 diabetes without diabetic retinopathy, p = p-value for linear
trend.
* Boldface values indicate p < 0.05.
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thinner compared with individuals with
NGM (range: b = 4.05 to 5.29 lm,
p < 0.001). All macular thicknesses
decreased with worsening of glucose
metabolism status, with a significant p-
value for linear trend for the fovea and
the pericentral macular thicknesses
(p < 0.001). There were no statistically
significant interactions between the
variables age, sex, spherical equivalent
and glucose metabolism status
(p > 0.10). These interaction terms
were, therefore, left out of the models.
Figure 4 shows the mean difference
(b) in pericentral macular thicknesses
in individuals with prediabetes and
DM2 w/o DR as compared with
NGM after adjustment for age, sex
and spherical equivalent. About half of
the thinning observed in DM2 w/o DR
was already found in prediabetes.
Thinning of the macula was more
pronounced with worsening of glucose
metabolism status, with a significant
linear trend for all quadrants
(p < 0.001).
Discussion
We show for the first time that predi-
abetes and further worsening of glu-
cose metabolism status are associated
with general thinning of the macula in
a population-based setting. About half
of the thinning observed in DM2 w/o
DR was already found in prediabetes.
These findings suggest that early neu-
rodegenerative changes are already
present in prediabetes, and that these
changes are more evident in individuals
with DM2 w/o DR in all subfields.
To our knowledge, this is the first
study on the association between glu-
cose metabolism status, as defined by
an OGTT, and changes in macular
thickness. In contrast to previous
studies, we used a highly detailed
volume scan consisting of 73 B-scans
with an excellent inter- and intra-
observer reliability to assess the macu-
lar thickness. The mean macular thick-
nesses of all subfields had a small
standard error and were very similar
between right and left eyes. In individ-
uals with NGM, the pericentral tem-
poral macula was thinner than the
other quadrants, which is also similar
to previous studies (Sanchez-Tocino
et al. 2002; Sugimoto et al. 2005;
Browning et al. 2008; Oshitari et al.
2009). Thinning of the different peri-
central macular subfields is consistent
with two previous studies using OCT in
individuals with DM2 w/o DR (Sugi-
moto et al. 2005; Oshitari et al. 2009).
We found a highly significant trend
of macular thinning from NGM via
prediabetes to DM2 w/o DR in all
pericentral subfields of both eyes.
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Fig. 3. Crude pericentral nasal macular thickness (A), pericentral superior macular thickness (B), pericentral temporal macular thickness (C) and
pericentral inferior macular thickness (D) for individuals with NGM, prediabetes and DM2 (Mean  SE). DM2 w/o DR = type 2 diabetes without
diabetic retinopathy, NGM = normal glucose metabolism.
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Previous studies also assessed the mac-
ular thickness in individuals with DM2
w/o DR. However, these studies
showed discrepancies in results regard-
ing centre thickness, foveal thickness
and pericentral macular thicknesses
(De Clerck et al. 2015). These discrep-
ancies may be explained by heterogene-
ity among these studies in terms of
sample size, population characteristics
and scan protocol. In addition, none of
these studies made adjustments for
basic confounding factors such as age,
sex and spherical equivalent. Similar to
previous studies, we found that ageing
is associated with macular thinning
(Massin et al. 2002; Sanchez-Tocino
et al. 2002; Chan et al. 2006; von
Hanno et al. 2017). We detected a
thinner macular thickness in women
compared with men. This has also been
described previously (Massin et al.
2002; Chamberlain et al. 2006; von
Hanno et al. 2017). Controversial
results have been reported for the
association between spherical equiva-
lent and macular thickness (Zou et al.
2006; Lam et al. 2007; Ooto et al.
2010, 2011; von Hanno et al. 2017).
We found a non-significant association
between a lower spherical equivalent
and macular thinning. Our findings
regarding the negative correlation
between macular thickness and dia-
betes duration in individuals with type
2 diabetes correspond with previous
research in individuals with type 1
diabetes (Sohn et al. 2016).
Macular thinning seems to reflect
early neurodegenerative changes in
diabetes. Therefore, our findings sup-
port the hypothesis that retinal neu-
rodegenerative changes occur before
the presence of microvascular changes
as assessed with conventional tech-
niques (Friedenwald 1950; Cogan et al.
1961; Barber 2003) and even before the
diagnosis of DM2. Previous studies
have shown that chronic hypergly-
caemia, oxidative stress and accumula-
tion of advanced glycation end
products result in an increase in the
concentration of glutamate and the loss
of neuroprotective factors. Animal
studies (Lieth et al. 1998; Barber
et al. 2000, 2005; Rungger-Brandle
et al. 2000; Zeng et al. 2000; Kim et al.
2004; Martin et al. 2004; Gastinger
et al. 2006; Tang et al. 2011; Bogdanov
et al. 2014; Arroba et al. 2016) and
human studies (Wolter 1961; Blood-
worth 1962; Barber et al. 1998; Mizu-
tani et al. 1998; Abu-El-Asrar et al.
2004) have demonstrated that these
insults can result in glial activation,
neuronal apoptosis, thinning of the
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Fig. 4. Mean difference in pericentral nasal macular thickness (A), pericentral superior macular thickness (B), pericentral temporal macular thickness
(C) and pericentral inferior macular thickness (D) in individuals with prediabetes and DM2 w/o DR as compared with individuals with NGM after
adjustment for age, sex and spherical equivalent. DM2 w/o DR = type 2 diabetes without diabetic retinopathy, NGM = normal glucose metabolism.
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neuronal layers in the retina and an
increase in vascular endothelial growth
factor. This leads to vasoregression, an
impaired hemodynamic response and a
breakdown of the blood-retinal barrier,
resulting in early microvascular
changes, and in a later stage to accu-
mulation of extravascular fluid, which
can result in cystoid macular oedema
(Cunha-Vaz et al. 1975; Simonett et al.
2017). Finally, inflammatory factors
and a low number or dysfunction of
endothelial progenitor cells also play a
role in these microvascular and neu-
rodegenerative changes (Simo & Her-
nandez 2014).
In prediabetes and DM2 w/o DR,
we observed macular thinning in all
subfields, whereas in the RNFL around
the optic nerve head, only the temporal
half was affected in our earlier study in
the same population (De Clerck et al.
2017). This may be explained by dam-
age to the papillo-macular bundle and
its neighbouring bundles emanating
from ganglion cells all over the macula,
together with their axons, forming
nerve fibre bundles predominantly con-
nected with the temporal RNFL
around the optic nerve head (Lee et al.
2012). This thinning reflects a decrease
in the number of retinal nerve fibres
and ganglion cells (van Dijk et al.
2010; Kim et al. 2015). Ganglion cells
are sensitive to oxidative stress and to
diabetes-related neurodegenerative
changes (Kergoat et al. 2006; Kern &
Barber 2008). Retinal nerve fibre layer
(RNFL) thinning around the optic
nerve head and macular thinning could
occur secondary to neuronal apoptosis
by metabolic stress or alterations in the
nerve fibre connections between the
optic nerve head and the macula.
Furthermore, parvocellular axons from
the papillo-macular bundle are more
sensitive to early metabolic changes
(Stricker et al. 2011).
A previous study showed preferen-
tial thinning of the inner retinal layers
in individuals with type 2 diabetes (van
Dijk et al. 2012). Recent studies sug-
gest that there is a direct relationship
between axonal loss and visual func-
tion, as a decrease in ganglion cells and
their axons, as measured by SD-OCT,
is related to visual field loss in individ-
uals with glaucoma (Bogunovic et al.
2015). Therefore, macular ganglion cell
parameters are not only affected in
individuals with diabetes, but also seem
to be more appropriate for the
diagnosis of glaucoma than measuring
the RNFL thickness around the optic
nerve head (Kim et al. 2011; Moreno
et al. 2011; Rimayanti et al. 2014; Ng
et al. 2015).
Neurodegenerative macular thinning
in prediabetes suggests that DR begins
in the earliest stages of glucose dysreg-
ulation, early in the progression from
NGM to frank diabetes, which lasts
7 years on average (Ramlo-Halsted &
Edelman 1999). This is an important
finding as glucose dysregulation is
amenable to treatment and may thus
be a target to prevent neurodegenera-
tive changes in the retina in DM2.
Early identification, lifestyle modifica-
tion and treatment of cardiovascular
risk factors in individuals with predia-
betes have the potential to reduce both
the incidence of diabetes and the DR
(McKinlay & Marceau 2000; Olafsdot-
tir et al. 2016; Larsen et al. 2017).
Therefore, the first step may be to
identify prediabetes rather than focus-
ing on detecting microvascular changes
using ophthalmoscopy to reduce the
burden of diabetes on ocular changes,
whether neuronal and (or) vascular.
Due to the later implementation of
the OCT measurements, it is possible
that our sample is not truly population-
based. The missing participants, how-
ever, were older, suggesting that, if
anything, macular thinning in the total
study population of the Maastricht
Study is expected to be greater than
reported here. This study has a cross-
sectional design and does not allow
conclusions on cause-and-effect rela-
tions. However, by comparing individ-
uals with NGM, prediabetes and DM2
w/o DR, we simulate the pathological
pathway of glucose metabolism deteri-
oration.
Future studies should focus on
causality and underlying mechanisms
of macular thinning in prediabetes and
DM2 and should also quantify the
thickness of the separate layers of the
retina, because these layers can be
affected differently by diabetes (van
Dijk et al. 2012). In addition, the link
between these structural changes and
functional changes, such as visual field
loss, needs to be studied further.
Moreover, future studies should assess
whether neurodegenerative changes in
the macula are related to the presence
of neuropathy and nephropathy in
individuals with prediabetes and
DM2.
In conclusion, macular thickness is
reduced in prediabetes and a greater
reduction occurs in DM2, even before
DR is clinically present. About half of
the thinning observed in DM2 w/o DR
was already found in prediabetes. Gen-
eralized thinning of the macula could
be related to thinning of the temporal
side of the optic nerve head through the
connecting papillo-macular bundle.
References
Abu-El-Asrar AM, Dralands L, Missotten L,
Al-Jadaan IA & Geboes K (2004): Expres-
sion of apoptosis markers in the retinas of
human subjects with diabetes. Invest Oph-
thalmol Vis Sci 45: 2760–2766.
American Academy of Ophthalmology Retina/
Vitreous Panel. Preferred Practice Pattern
Guidelines (2014): Diabetic retinopathy. San
Francisco, CA: American Academy of Oph-
thalmology. Available at: www.aao.org/ppp.
(Accessed on 12 Aug 2015).
Arroba AI, Mazzeo A, Cazzoni D, Beltramo
E, Hernandez C, Porta M, Simo R &
Valverde AM (2016): Somatostatin protects
photoreceptor cells against high glucose-
induced apoptosis. Mol Vis 22: 1522–1531.
Barber AJ (2003): A new view of diabetic
retinopathy: a neurodegenerative disease of
the eye. Prog Neuropsychopharmacol Biol
Psychiatry 27: 283–290.
Barber AJ, Lieth E, Khin SA, Antonetti DA,
Buchanan AG & Gardner TW (1998): Neu-
ral apoptosis in the retina during experi-
mental and human diabetes. Early onset and
effect of insulin. J Clin Invest 102: 783–791.
Barber AJ, Antonetti DA & Gardner TW
(2000): Altered expression of retinal occlu-
din and glial fibrillary acidic protein in
experimental diabetes. The Penn State
Retina Research Group. Invest Ophthal
Vis Sci 41: 3561–3568.
Barber AJ, Antonetti DA, Kern TS et al.
(2005): The Ins2Akita mouse as a model of
early retinal complications in diabetes.
Invest Ophthalmol Vis Sci 46: 2210–2218.
Bearse MA Jr, Adams AJ, Han Y, Schneck
ME, Ng J, Bronson-Castain K & Barez S
(2006): A multifocal electroretinogram
model predicting the development of dia-
betic retinopathy. Prog Retin Eye Res 25:
425–448.
Bloodworth JM Jr (1962): Diabetic retinopa-
thy. Diabetes 11: 1–22.
Bogdanov P, Corraliza L, Villena JA et al.
(2014): The db/db mouse: a useful model for
the study of diabetic retinal neurodegenera-
tion. PLoS ONE 9: e97302.
Bogunovic H, Kwon YH, Rashid A, Lee K,
Critser DB, Garvin MK, Sonka M &
Abramoff MD (2015): Relationships of reti-
nal structure and humphrey 24-2 visual field
thresholds in patients with glaucoma. Invest
Ophthalmol Vis Sci 56: 259–271.
180
Acta Ophthalmologica 2018
Bresnick GH (1986): Diabetic retinopathy
viewed as a neurosensory disorder. Arch
Ophthalmol 104: 989–990.
Browning DJ, Fraser CM & Clark S (2008):
The relationship of macular thickness to
clinically graded diabetic retinopathy sever-
ity in eyes without clinically detected dia-
betic macular edema. Ophthalmology 115:
533–539.e532.
Carrasco E, Hernandez C, Miralles A, Huguet
P, Farres J & Simo R (2007): Lower
somatostatin expression is an early event in
diabetic retinopathy and is associated with
retinal neurodegeneration. Diabetes Care
30: 2902–2908.
Carrasco E, Hernandez C, de Torres I, Farres
J & Simo R (2008): Lowered cortistatin
expression is an early event in the human
diabetic retina and is associated with apop-
tosis and glial activation. Mol Vis 14: 1496–
1502.
Chamberlain MD, Guymer RH, Dirani M,
Hopper JL & Baird PN (2006): Heritability
of macular thickness determined by optical
coherence tomography. Invest Ophthalmol
Vis Sci 47: 336–340.
Chan A, Duker JS, Ko TH, Fujimoto JG &
Schuman JS (2006): Normal macular thick-
ness measurements in healthy eyes using
Stratus optical coherence tomography. Arch
Ophthalmol 124: 193–198.
Cogan DG, Toussaint D & Kuwabara T
(1961): Retinal vascular patterns. IV. Dia-
betic retinopathy. Arch Ophthalmol 66:
366–378.
Cunha-Vaz J, Faria de Abreu JR & Campos
AJ (1975): Early breakdown of the blood-
retinal barrier in diabetes. Br J Ophthalmol
59: 649–656.
De Clerck EE, Schouten JS, Berendschot TT
et al. (2015): New ophthalmologic imaging
techniques for detection and monitoring of
neurodegenerative changes in diabetes: a
systematic review. Lancet Diabetes Endocri-
nol 3: 653–663.
De Clerck EE, Schouten JS, Berendschot TT,
Beckers HJ, Schaper NC, Schram MT,
Stehouwer CD & Webers CA (2017): Loss
of temporal peripapillary retinal nerve fibers
in prediabetes or type 2 diabetes without
diabetic retinopathy: The Maastricht Study.
Invest Ophthalmol Vis Sci 58: 1017–1027.
van Dijk HW, Verbraak FD, Kok PH et al.
(2010): Decreased retinal ganglion cell layer
thickness in patients with type 1 diabetes.
Invest Ophthalmol Vis Sci 51: 3660–3665.
van Dijk HW, Verbraak FD, Kok PH et al.
(2012): Early neurodegeneration in the
retina of type 2 diabetic patients. Invest
Ophthalmol Vis Sci 53: 2715–2719.
Friedenwald JS (1950): Diabetic retinopathy.
Am J Ophthalmol 33: 1187–1199.
Frost-Larsen K, Larsen HW & Simonsen SE
(1980): Oscillatory potential and nyctometry
in insulin-dependent diabetics. Acta Oph-
thalmol (Copenh) 58: 879–888.
Garcia-Ramirez M, Hernandez C, Villarroel
M et al. (2009): Interphotoreceptor retinoid-
binding protein (IRBP) is downregulated at
early stages of diabetic retinopathy. Dia-
betologia 52: 2633–2641.
Gardner TW, Abcouwer SF, Barber AJ &
Jackson GR (2011): An integrated approach
to diabetic retinopathy research. Arch Oph-
thalmol 129: 230–235.
Gastinger MJ, Singh RS & Barber AJ (2006):
Loss of cholinergic and dopaminergic ama-
crine cells in streptozotocin-diabetic rat and
Ins2Akita-diabetic mouse retinas. Invest
Ophthalmol Vis Sci 47: 3143–3150.
Han Y, Adams AJ, Bearse MA Jr & Schneck
ME (2004a): Multifocal electroretinogram
and short-wavelength automated perimetry
measures in diabetic eyes with little or no
retinopathy. Arch Ophthalmol 122: 1809–
1815.
Han Y, Bearse MA Jr, Schneck ME, Barez S,
Jacobsen CH & Adams AJ (2004b): Multi-
focal electroretinogram delays predict sites
of subsequent diabetic retinopathy. Invest
Ophthalmol Vis Sci 45: 948–954.
von Hanno T, Lade AC, Mathiesen EB, Peto
T, Njolstad I & Bertelsen G (2017): Macular
thickness in healthy eyes of adults
(N = 4508) and relation to sex, age and
refraction: the Tromso Eye Study (2007-
2008). Acta Ophthalmol 95: 262–269.
Hardy KJ, Lipton J, Scase MO, Foster DH &
Scarpello JH (1992): Detection of colour
vision abnormalities in uncomplicated type 1
diabetic patients with angiographically nor-
mal retinas. Br J Ophthalmol 76: 461–464.
Harrison WW, Bearse MA Jr, Ng JS, Jewell
NP, Barez S, Burger D, Schneck ME &
Adams AJ (2011): Multifocal electroretino-
grams predict onset of diabetic retinopathy
in adult patients with diabetes. Invest Oph-
thalmol Vis Sci 52: 772–777.
Henson DB & North RV (1979): Dark adap-
tation in diabetes mellitus. Br J Ophthalmol
63: 539–541.
Kergoat H, Herard ME & Lemay M (2006):
RGC sensitivity to mild systemic hypoxia.
Invest Ophthalmol Vis Sci 47: 5423–5427.
Kern TS & Barber AJ (2008): Retinal ganglion
cells in diabetes. J Physiol 586: 4401–4408.
Kim SY, Johnson MA, McLeod DS, Alexan-
der T, Otsuji T, Steidl SM, Hansen BC &
Lutty GA (2004): Retinopathy in monkeys
with spontaneous type 2 diabetes. Invest
Ophthalmol Vis Sci 45: 4543–4553.
Kim NR, Lee ES, Seong GJ, Kang SY, Kim
JH, Hong S & Kim CY (2011): Comparing
the ganglion cell complex and retinal nerve
fibre layer measurements by Fourier domain
OCT to detect glaucoma in high myopia. Br
J Ophthalmol 95: 1115–1121.
KimMJ, Park KH, Yoo BW, Jeoung JW, Kim
HC & Kim DM (2015): Comparison of
macular GCIPL and peripapillary RNFL
deviation maps for detection of glaucoma-
tous eye with localized RNFL defect. Acta
Ophthalmol 93: e22–e28.
Klemp K, Sander B, Brockhoff PB, Vaag A,
Lund-Andersen H & Larsen M (2005): The
multifocal ERG in diabetic patients without
retinopathy during euglycemic clamping.
Invest Ophthalmol Vis Sci 46: 2620–2626.
Lam DS, Leung KS, Mohamed S et al. (2007):
Regional variations in the relationship
between macular thickness measurements
and myopia. Invest Ophthalmol Vis Sci 48:
376–382.
Larsen MB, Henriksen JE, Grauslund J &
Peto T (2017): Prevalence and risk factors
for diabetic retinopathy in 17 152 patients
from the island of Funen, Denmark. Acta
Ophthalmol [Epub ahead of print].
Lee K, Kwon YH, Garvin MK, Niemeijer M,
Sonka M & Abramoff MD (2012): Distri-
bution of damage to the entire retinal
ganglion cell pathway: quantified using
spectral-domain optical coherence tomogra-
phy analysis in patients with glaucoma.
Arch Ophthalmol 130: 1118–1126.
Lieth E, Barber AJ, Xu B, Dice C, Ratz MJ,
Tanase D & Strother JM (1998): Glial
reactivity and impaired glutamate metabo-
lism in short-term experimental diabetic
retinopathy. Penn State Retina Research
Group. Diabetes 47: 815–820.
MartinPM,RoonP,VanElls TK,GanapathyV
&SmithSB (2004):Deathof retinalneurons in
streptozotocin-induced diabetic mice. Invest
Ophthalmol Vis Sci 45: 3330–3336.
Massin P, Erginay A, Haouchine B, Mehidi
AB, Paques M & Gaudric A (2002): Retinal
thickness in healthy and diabetic subjects
measured using optical coherence tomogra-
phy mapping software. Eur J Ophthalmol
12: 102–108.
McKinlay J & Marceau L (2000): US public
health and the 21st century: diabetes melli-
tus. Lancet 356: 757–761.
Mizutani M, Gerhardinger C & Lorenzi M
(1998): Muller cell changes in human dia-
betic retinopathy. Diabetes 47: 445–449.
Moreno PA, Konno B, Lima VC et al. (2011):
Spectral-domain optical coherence tomog-
raphy for early glaucoma assessment: anal-
ysis of macular ganglion cell complex versus
peripapillary retinal nerve fiber layer. Can J
Ophthal 46: 543–547.
Ng JS, Bearse MA Jr, Schneck ME, Barez S &
Adams AJ (2008): Local diabetic retinopa-
thy prediction by multifocal ERG delays
over 3 years. Invest Ophthalmol Vis Sci 49:
1622–1628.
Ng DS, Gupta P, Tham YC, Peck CF, Wong
TY, Ikram MK & Cheung CY (2015):
Repeatability of perimacular ganglion cell
complex analysis with spectral-domain opti-
cal coherence tomography. J Ophthalmol
2015: 605940.
Olafsdottir E, Andersson DK, Dedorsson I,
Svardsudd K, Jansson SP & Stefansson E
(2016): Early detection of type 2 diabetes
mellitus and screening for retinopathy are
associated with reduced prevalence and
severity of retinopathy. Acta Ophthalmol
94: 232–239.
Ooto S, Hangai M, Sakamoto A et al. (2010):
Three-dimensional profile of macular retinal
thickness in normal Japanese eyes. Invest
Ophthalmol Vis Sci 51: 465–473.
Ooto S, Hangai M, Tomidokoro A et al.
(2011): Effects of age, sex, and axial length
181
Acta Ophthalmologica 2018
on the three-dimensional profile of normal
macular layer structures. Invest Ophthalmol
Vis Sci 52: 8769–8779.
Oshitari T, Hanawa K & Adachi-Usami E
(2009): Changes of macular and RNFL
thicknesses measured by Stratus OCT in
patients with early stage diabetes. Eye 23:
884–889.
Ramlo-Halsted BA & Edelman SV (1999): The
natural history of type 2 diabetes. Implica-
tions for clinical practice. Prim Care 26:
771–789.
Realini T, Lai MQ & Barber L (2004): Impact
of diabetes on glaucoma screening using
frequency-doubling perimetry. Ophthalmol-
ogy 111: 2133–2136.
Rimayanti U, Latief MA, Arintawati P, Akita
T, Tanaka J & Kiuchi Y (2014): Width of
abnormal ganglion cell complex area deter-
mined using optical coherence tomography
to predict glaucoma. Jpn J Ophthalmol 58:
47–55.
Rungger-Brandle E, Dosso AA & Leuenberger
PM (2000): Glial reactivity, an early feature
of diabetic retinopathy. Invest Ophthalmol
Vis Sci 41: 1971–1980.
Sanchez-Tocino H, Alvarez-Vidal A, Maldon-
ado MJ, Moreno-Montanes J & Garcia-
Layana A (2002): Retinal thickness study
with optical coherence tomography in
patients with diabetes. Invest Ophthalmol
Vis Sci 43: 1588–1594.
Schram MT, Sep SJ, van der Kallen CJ,
Dagnelie PC, Koster A, Schaper N, Henry
RM & Stehouwer CD (2014): The Maas-
tricht Study: an extensive phenotyping study
on determinants of type 2 diabetes, its
complications and its comorbidities. Eur J
Epidemiol 29: 439–451.
Simo R, Hernandez C & European Consor-
tium for the Early Treatment of Diabetic
Retinopathy (2014): Neurodegeneration in
the diabetic eye: new insights and therapeu-
tic perspectives. Trends Endocrinol Metab
25: 23–33.
Simonett JM, Scarinci F, Picconi F et al.
(2017): Early microvascular retinal changes
in optical coherence tomography angiogra-
phy in patients with type 1 diabetes mellitus.
Acta Ophthalmol [Epub ahead of print].
Simonsen SE (1980): The value of the oscilla-
tory potential in selecting juvenile diabetics
at risk of developing proliferative retinopa-
thy. Acta Ophthalmol (Copenh) 58: 865–
878.
Sohn EH, van Dijk HW, Jiao C et al. (2016):
Retinal neurodegeneration may precede
microvascular changes characteristic of
diabetic retinopathy in diabetes mellitus.
Proc Natl Acad Sci USA 113: E2655–
E2664.
Sokol S, Moskowitz A, Skarf B, Evans R,
Molitch M & Senior B (1985): Contrast
sensitivity in diabetics with and without
background retinopathy. Arch Ophthalmol
103: 51–54.
Stricker S, Oberwahrenbrock T, Zimmer-
mann H, Schroeter J, Endres M, Brandt
AU & Paul F (2011): Temporal retinal
nerve fiber loss in patients with spinocere-
bellar ataxia type 1. PLoS ONE 6:
e23024.
Sugimoto M, Sasoh M, Ido M, Wakitani Y,
Takahashi C & Uji Y (2005): Detection of
early diabetic change with optical coherence
tomography in type 2 diabetes mellitus
patients without retinopathy. Ophthalmo-
logica 219: 379–385.
Tang L, Zhang Y, Jiang Y, Willard L, Ortiz E,
Wark L, Medeiros D & Lin D (2011):
Dietary wolfberry ameliorates retinal struc-
ture abnormalities in db/db mice at the early
stage of diabetes. Exp Biol Med 236: 1051–
1063.
Vujosevic S, Pilotto E, Bottega E, Benetti E,
Cavarzeran F & Midena E (2008): Retinal
fixation impairment in diabetic macular
edema. Retina 28: 1443–1450.
Wolter JR (1961): Diabetic retinopathy. Am J
Ophthalmol 51: 1123–1141.
World Health Organization (2006): Definition
and diagnosis of diabetes mellitus and
intermediate hyperglycemia: report of a
WHO/IDF consultation. Geneva, Switzer-
land.
Zeng XX, Ng YK & Ling EA (2000): Neu-
ronal and microglial response in the retina
of streptozotocin-induced diabetic rats. Vis
Neurosci 17: 463–471.
Zou H, Zhang X, Xu X & Yu S (2006):
Quantitative in vivo retinal thickness mea-
surement in chinese healthy subjects with
retinal thickness analyzer. Invest Ophthal-
mol Vis Sci 47: 341–347.
Received on April 2nd, 2017.
Accepted on July 30th, 2017.
Correspondence:
Eline E.B. De Clerck, MD
University Eye Clinic Maastricht
PO Box 5800
NL-6202 AZ Maastricht
The Netherlands
Tel: +31 6 36143602
Fax: +31 43 3875343
Email: eline.de.clerck@mumc.nl
The Regional Association of General Practi-
tioners (Zorg in Ontwikkeling) is gratefully
acknowledged for their contribution to The
Maastricht Study, enabling the invitation of
individuals with type 2 diabetes using informa-
tion from their web-based electronic health
record. This research was supported by grant
122047 from Fonds NutsOhra, The Nether-
lands. TheMaastricht Study was supported by
the EuropeanRegional Development Fund via
OP-Zuid, the Province of Limburg, the Dutch
Ministry of Economic Affairs (grant 31O.041),
Stichting De Weijerhorst (Maastricht, The
Netherlands), the Pearl String Initiative Dia-
betes (Amsterdam, The Netherlands), the Car-
diovascular Center (CVC, Maastricht, The
Netherlands), Cardiovascular Research Insti-
tute Maastricht (CARIM, Maastricht, The
Netherlands), School for Public Health and
Primary Care (CAPHRI, Maastricht, The
Netherlands), School for Nutrition, Toxicol-
ogy and Metabolism (NUTRIM, Maastricht,
The Netherlands), Stichting Annadal (Maas-
tricht, The Netherlands), Health Foundation
Limburg (Maastricht, The Netherlands) and
by unrestricted grants from Janssen-Cilag B.V.
(Tilburg, The Netherlands), Novo Nordisk
Farma B.V. (Alphen aan den Rijn, The
Netherlands) and Sanofi-Aventis Netherlands
B.V. (Gouda, The Netherlands). Equipment
was supplied by Heidelberg Engineering and
the University Eye Clinic Maastricht.
182
Acta Ophthalmologica 2018
